Reduced intensity conditioning stem cell transplantation for lymphoid and myeloid malignancies in Australia and New Zealand

Not Applicable

Completed

• Conditions: Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma; acute myeloid leukemia; myelodysplastic syndrome; non Hodgkins lymphoma; chronic lymphocytic leukemia; myelofibrosis; Hodgkin's lymphoma; acute biphenotypic leukemia; Cancer - Leukaemia - Acute leukaemia; Cancer - Leukaemia - Chronic leukaemia

• Registration Number: ACTRN12612000575831
• Lead Sponsor: Australian Bone Marrow Transplant Recipient Registry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

first allogeneic peripheral blood or bone marrow HSCT using Fludarabine Melphalan conditioning for lymphoid and myeloid malignancies between January 1998 and December 2008

Exclusion Criteria

multiple myeloma
acute lymphoblastic leukemia
prior allogeneic HSCT

Study & Design

• Study Type: Observational
• Study Design: Not specified